JO3737B1 - تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان - Google Patents
تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطانInfo
- Publication number
- JO3737B1 JO3737B1 JOP/2016/0149A JOP20160149A JO3737B1 JO 3737 B1 JO3737 B1 JO 3737B1 JO P20160149 A JOP20160149 A JO P20160149A JO 3737 B1 JO3737 B1 JO 3737B1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer
- inhibitor
- treatment
- orally administered
- administered paclitaxel
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title abstract 4
- 229960001592 paclitaxel Drugs 0.000 title abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 title abstract 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000008389 polyethoxylated castor oil Substances 0.000 abstract 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<span dir="RTL">يتعلق الطلب الحالي بتركيبات دوائية لجرعة من علاج باكليتاكسيل عن طريق الفم ومثبط </span>P-GP<span dir="RTL"> هذه التركيبات الدوائية مناسبة لعلاج السرطان في مستهدف بالعلاج للحد من أو لمنع تفاعلات السمية أو نقيع فرط الحساسية والنتائج السلبية الأخرى الناتجة عن أو المترافقة مع إعطاء جرعة من باكليتاكسيل تعطى عن طريق الوريد (على سبيل المثال، </span>Taxol®<span dir="RTL"> أو باكليتاكسيل يتم صياغته مع </span>Cremophor®<span dir="RTL"> لعلاج مستهدف يعاني من مرض السرطان</span>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195243P | 2015-07-21 | 2015-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3737B1 true JO3737B1 (ar) | 2021-01-31 |
Family
ID=57833861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0149A JO3737B1 (ar) | 2015-07-21 | 2016-07-20 | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180207148A1 (ar) |
| EP (1) | EP3324968B1 (ar) |
| CN (2) | CN108135895A (ar) |
| AU (3) | AU2016295357B2 (ar) |
| CA (1) | CA2993127C (ar) |
| JO (1) | JO3737B1 (ar) |
| MX (2) | MX389270B (ar) |
| TW (1) | TWI760306B (ar) |
| WO (1) | WO2017013490A2 (ar) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI715636B (zh) * | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| CN112351779A (zh) * | 2018-04-13 | 2021-02-09 | 慧源医疗有限公司 | 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合 |
| CN113631166A (zh) * | 2018-12-14 | 2021-11-09 | 慧源香港创新有限公司 | 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合 |
| MX2024003037A (es) * | 2021-09-10 | 2024-07-30 | Health Hope Pharma Ltd | Combinaciones terapéuticas de paclitaxel administrado por vía oral, un inhibidor de p-gp, y un inhibidor de punto de control para el tratamiento de tumores sólidos. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| RU2002113659A (ru) * | 1999-10-27 | 2004-01-27 | Бейкер Нортон Фармасьютикалз, Инк. (Us) | Способ и композиции для перорального введения таксанов больным людям |
| WO2003094967A2 (en) * | 2002-05-07 | 2003-11-20 | Altana Pharma Ag | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
| KR100557093B1 (ko) * | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CN112351779A (zh) * | 2018-04-13 | 2021-02-09 | 慧源医疗有限公司 | 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合 |
-
2016
- 2016-07-20 JO JOP/2016/0149A patent/JO3737B1/ar active
- 2016-07-21 EP EP16827318.3A patent/EP3324968B1/en active Active
- 2016-07-21 TW TW105123085A patent/TWI760306B/zh active
- 2016-07-21 AU AU2016295357A patent/AU2016295357B2/en active Active
- 2016-07-21 WO PCT/IB2016/001132 patent/WO2017013490A2/en not_active Ceased
- 2016-07-21 CN CN201680054929.XA patent/CN108135895A/zh active Pending
- 2016-07-21 MX MX2018000872A patent/MX389270B/es unknown
- 2016-07-21 US US15/745,490 patent/US20180207148A1/en not_active Abandoned
- 2016-07-21 CN CN202211612201.8A patent/CN115778956A/zh active Pending
- 2016-07-21 CA CA2993127A patent/CA2993127C/en active Active
-
2018
- 2018-01-19 MX MX2022000394A patent/MX2022000394A/es unknown
-
2021
- 2021-07-26 AU AU2021209160A patent/AU2021209160A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/959,470 patent/US20230172926A1/en active Pending
-
2023
- 2023-09-15 AU AU2023229590A patent/AU2023229590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021209160A1 (en) | 2021-08-19 |
| EP3324968A4 (en) | 2019-04-10 |
| EP3324968A2 (en) | 2018-05-30 |
| AU2016295357B2 (en) | 2021-05-13 |
| TW201716064A (zh) | 2017-05-16 |
| WO2017013490A2 (en) | 2017-01-26 |
| WO2017013490A3 (en) | 2017-03-02 |
| EP3324968C0 (en) | 2023-09-27 |
| TWI760306B (zh) | 2022-04-11 |
| MX2018000872A (es) | 2018-08-15 |
| AU2016295357A1 (en) | 2018-02-15 |
| NZ739270A (en) | 2024-10-25 |
| CA2993127A1 (en) | 2017-01-26 |
| MX389270B (es) | 2025-03-20 |
| CN108135895A (zh) | 2018-06-08 |
| MX2022000394A (es) | 2022-02-10 |
| HK1256017A1 (en) | 2019-09-13 |
| US20230172926A1 (en) | 2023-06-08 |
| AU2023229590A1 (en) | 2023-10-05 |
| CA2993127C (en) | 2023-10-17 |
| CN115778956A (zh) | 2023-03-14 |
| US20180207148A1 (en) | 2018-07-26 |
| EP3324968B1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| NZ716765A (en) | Pharmaceutical combinations for the treatment of cancer | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| MX381526B (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
| UA95037U (uk) | Спосіб лікування неалкогольного стеатогепатиту | |
| UA104733U (uk) | Спосіб лікування гастропатій у пацієнтів з хронічним обструктивним захворюванням легень | |
| HK1204956A1 (zh) | 癌症治療 | |
| UA99921U (ru) | Способ контролируемой седации у пациентов с состоянием отмены алкоголя в отделении интенсивной терапии |